JPMorgan Starts Allogene (ALLO) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Cowen Starts Allogene (ALLO) at Outperform
November 5, 2018 5:35 AM ESTCowen analyst Phil Nadeau initiates coverage on Allogene (NASDAQ: ALLO) with a Outperform rating.
The analyst comments "Allogene is the leading company in the development of allogeneic CAR T therapies for the treatment of cancer. Candidate UCART19 has produced proof of... More
Goldman Sachs Starts Allogene (ALLO) at Buy
November 5, 2018 4:24 AM ESTGoldman Sachs analyst Salveen Richter initiates coverage on Allogene (NASDAQ: ALLO) with a Buy rating and a price target of $41.00.
The analyst is positive citing near-term catalysts in ASH (December) with an update on UCART 19, ASCO 2019 and ASH 2019 which is critical due... More
Jefferies Starts Allogene (ALLO) at Buy
November 5, 2018 4:11 AM ESTJefferies analyst Biren Amin initiates coverage on Allogene (NASDAQ: ALLO) with a Buy rating and a price target of $31.00.
The analyst comments "ALLO is developing a deep portfolio of allogeneic CAR-T assets, centered on gene-editing tech and state-of-the-art cell mfr capabilities. ALLO would potentially provide... More
